Terms: = Breast cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
5598 results:
1. Clinicopathologic features and genomic profiling of female axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary.
Tang L; Zhu Y; Du Y; Long X; Long Y; Tang Y; Liu J
J Cancer Res Clin Oncol; 2024 May; 150(5):256. PubMed ID: 38750402
[TBL] [Abstract] [Full Text] [Related]
2. RPGRIP1L as a new biomarker for prognosis and tumor immune of breast cancer.
Yi J; Liu L; Chen Y; Ding T; Fan P; Yu J; Zeng J
FASEB J; 2024 May; 38(9):e23624. PubMed ID: 38747001
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for her2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Man X; Huang J; Sun S; Zhou D; Zhang B; Fang S; Zheng F; Li C; Wang X; Huang W; Wang L; He Q; Fu H; Zhang Y; Liu C; Dong L; Zhao X; Xu L; Sun X; Fan B; Song L; Zhou Z; Yu J; Li H
Clin Transl Med; 2024 May; 14(5):e1687. PubMed ID: 38738791
[TBL] [Abstract] [Full Text] [Related]
4. Metaplastic breast cancer with a unique presentation and complete response to chemotherapy: a case report.
Nahhat F; Doyya M; Zabad K; Ksiri H
BMC Womens Health; 2024 May; 24(1):285. PubMed ID: 38734591
[TBL] [Abstract] [Full Text] [Related]
5. CD163
Omilian AR; Cannioto R; Mendicino L; Stein L; Bshara W; Qin B; Bandera EV; Zeinomar N; Abrams SI; Hong CC; Yao S; Khoury T; Ambrosone CB
Breast Cancer Res; 2024 May; 26(1):75. PubMed ID: 38720366
[TBL] [Abstract] [Full Text] [Related]
6. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
[TBL] [Abstract] [Full Text] [Related]
7. T-reg transcriptomic signatures identify response to check-point inhibitors.
Noblejas-López MDM; García-Gil E; Pérez-Segura P; Pandiella A; Győrffy B; Ocaña A
Sci Rep; 2024 May; 14(1):10396. PubMed ID: 38710724
[TBL] [Abstract] [Full Text] [Related]
8. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in her2-positive and her2-negative breast cancer patients.
Thonusin C; Osataphan N; Leemasawat K; Nawara W; Sriwichaiin S; Supakham S; Gunaparn S; Apaijai N; Somwangprasert A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
J Transl Med; 2024 Apr; 22(1):398. PubMed ID: 38685030
[TBL] [Abstract] [Full Text] [Related]
9. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract] [Full Text] [Related]
10. Lesion attention guided neural network for contrast-enhanced mammography-based biomarker status prediction in breast cancer.
Qian N; Jiang W; Wu X; Zhang N; Yu H; Guo Y
Comput Methods Programs Biomed; 2024 Jun; 250():108194. PubMed ID: 38678959
[TBL] [Abstract] [Full Text] [Related]
11. Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B breast cancer: A Pilot Study.
Camargo-Herrera V; Castellanos G; Rangel N; Jiménez-Tobón GA; Martínez-Agüero M; Rondón-Lagos M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674062
[TBL] [Abstract] [Full Text] [Related]
12. Impact of Pregnancy on breast cancer Features and prognosis.
Bounous VE; Minella C; Fuso L; Actis S; Petroni G; Sgrò LG; Borghese M; Tomasi Cont N; Ponzone R; Ferrero A
Curr Oncol; 2024 Apr; 31(4):2305-2315. PubMed ID: 38668074
[TBL] [Abstract] [Full Text] [Related]
13. The evolvement of breast cancer therapies: What we have done and where all these head off.
Nurlaila I; Pambudi S
Saudi Med J; 2024 Apr; 45(4):331-340. PubMed ID: 38657992
[TBL] [Abstract] [Full Text] [Related]
14. CyTOF analysis revealed platelet heterogeneity in breast cancer patients received T-DM1 treatment.
Ma J; Pang Y; Shang Y; Xie C; Xu X; Chan L; Zhang Z; Wang W
Clin Immunol; 2024 Jun; 263():110227. PubMed ID: 38643891
[TBL] [Abstract] [Full Text] [Related]
15. PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative breast cancer.
Wang SH; Yeh CH; Wu CW; Hsu CY; Tsai EM; Hung CM; Wang YW; Hsieh TH
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612711
[TBL] [Abstract] [Full Text] [Related]
16. Dual amplification for PEC ultrasensitive aptasensing of biomarker her-2 based on Z-scheme UiO-66/CdIn
Ai QY; Xu BF; Xu F; Wang AJ; Mei LP; Wu L; Song P; Feng JJ
Talanta; 2024 Jul; 274():126034. PubMed ID: 38604040
[TBL] [Abstract] [Full Text] [Related]
17. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
[TBL] [Abstract] [Full Text] [Related]
18. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/her2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
Peng J; Hong Y; Chen Q; Xu F; Zhang D; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Wang S; Yi W
Front Endocrinol (Lausanne); 2024; 15():1347762. PubMed ID: 38567311
[TBL] [Abstract] [Full Text] [Related]
19. The prognosis of patients treated with everolimus for advanced ER-positive, her2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract] [Full Text] [Related]
20. The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
Ye JH; Yu J; Huang MY; Mo YM
Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
[TBL] [Abstract] [Full Text] [Related]
[Next]
